AURN001 for Corneal Edema

This trial tests a new treatment called AURN001, an experimental therapy, to determine its safety and effectiveness for individuals with corneal edema. This condition causes eye swelling due to corneal endothelial dysfunction. Participants will receive either a single injection of AURN001 or a placebo for comparison. The trial seeks individuals with corneal edema severe enough to require surgery and who have an artificial lens implant. The study aims to determine if AURN001 can reduce eye swelling and improve vision. As a Phase 3 trial, this is the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that AURN001 is generally safe based on past studies. In these trials, many patients with corneal edema (swelling in the eye's cornea) tolerated AURN001 well. The studies did not find any serious safety issues. Some mild side effects occurred, but they were uncommon. This evidence suggests that AURN001 is generally safe for people with corneal edema due to corneal endothelial dysfunction.¹²³⁴⁵

AURN001 is unique because it offers a new approach to treating corneal edema. Unlike existing treatments, which often include hypertonic saline ointments or drops to reduce swelling, AURN001 is designed to work differently by potentially targeting underlying cellular mechanisms that contribute to the condition. Researchers are excited about AURN001 because it could provide faster relief and longer-lasting results, improving patient comfort and vision more effectively than current options.

Research has shown that AURN001 holds promise for treating corneal edema, a condition where the cornea swells due to excess fluid. In earlier studies, patients who received a high dose of AURN001 improved their vision by an average of 12.5 letters on an eye chart. These patients also experienced a reduction in corneal thickness by 23.2 micrometers, which helps clear vision. The treatment significantly improved both vision and quality of life for individuals with corneal endothelial dysfunction. In this trial, participants will receive either a single dose of AURN001 or a placebo control. These findings suggest that AURN001 could effectively treat corneal edema.⁴⁵⁶⁷⁸